Company / Net Income
KalVista Pharmaceuticals, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$183.4M
FY2025
5-year range
-$183.4M / -$82.3M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#151 of 216
Health Care
What the data says
At -$183M, KalVista Pharmaceuticals, Inc.'s net income ranks #151 of 216 in the Health Care sector. Declined from -$127M to -$183M over the past 2 years.
Based on SEC 10-K filings.
-$183M in FY2025.
Declined from -$127M to -$183M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#151 of 216 in Health CareTop 70% of 216This company -$183.4M Sector average $454.1M
▼
-140.4% below sector average
Key checks
Key Insights
- In FY2025, net income increased 0.0% year-over-year.
- Ranks #151 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$183.4M | +0.0% |
| FY2024 | -$183.4M | -44.9% |
| FY2023 | -$126.6M | -36.3% |
| FY2022 | -$92.9M | -12.8% |
| FY2021 | -$82.3M | -78.1% |
| FY2020 | -$46.2M | -148.6% |
| FY2019 | -$18.6M | -62.7% |
| FY2018 | -$11.4M | +27.6% |
| FY2017 | -$15.8M | +15.0% |
| FY2016 | -$18.6M | -62.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026